Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir

被引：12

作者：

Wedemeyer, H. ^{[1
]}

Hui, A. J. ^{[2
]}

Sukeepaisarnjaroen, W. ^{[3
]}

Tangkijvanich, P. ^{[4
]}

Su, W. W. ^{[5
]}

Nieto, G. E. G. ^{[6
]}

Gineste, P. ^{[7
]}

Nitcheu, J. ^{[7
]}

Crabe, S. ^{[7
]}

Stepien, S. ^{[8
]}

Cornberg, M. ^{[1
]}

Trepo, C. ^{[9
]}

机构：

[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

[2] Alice Ho Miu Ling Nethersole Hosp, Hong Kong, Hong Kong, Peoples R China

[3] Khon Kaen Univ, Khon Kaen, Thailand

[4] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[5] Changhua Christian Hosp, Taipei, Taiwan

[6] Ctr Ingn Genet & Biotecnol, Havana, Cuba

[7] ABIVAX, Paris, France

[8] Georges Inst, Sydney, NSW, Australia

[9] INSERM 1052 CRCL, Lyon, France

来源：

关键词：

D O I：

10.1016/S0168-8278(17)30463-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LBP-518

引用

页码：S101 / S101

页数：1